Genmab — Maj 2019

[E_L]

=BCMA/CD3

[Solsen]

Sounds
very nice. EGFR + cMet are double digit.

[Sukkeralf]

I have a feeling that Janssen keeps BCMA/CD3 under the radar - and suddenly pops up with the best data and a faster way to market. Just repeating the CD38 race

[Sukkeralf]

And in the future maybe in combination with dara

[Helge_LarsenPI-redaktør]

Welcome to Genmab

(www.genmab.com)

[Sukkeralf]

We are getting so close to good clinical vallidation of DuoBody and one could wish for good data on DR5/DR5 also - then both platforms are vallidated which make Genmabs money drain more accep
table

[gentogen]

https://johnsonandjohnson.gcs-web.com/static-files/7b8bef74-237e-4a05-82c3-79a8f8789f89

[gentogen]

slide 21

[E_L]

yes, very true Sukkeralf. (thanks @gentogen , i couldnt find it)

[Solsen]

Jnj 7564 er vel også Genmabs

[Sukkeralf]

Ja faktisk 3 stk - fantastisk

[Solsen]

JNJ-7564 GPRC5D/CD3, JNJ-7957 BCMA/CD3, JNJ-6372 EGFR/c-Met ...

[Solsen]

Ketchubeffekten

[Solsen]

Manden er komplet i....

[E_L]

haha, true, i was so excited about the 1st 1 already

[Solsen]

JNJ, Novo, Lundbeck, Novartis m.fl. kan hjælpe os med en god moneystream fremover...

[Solsen]

Genmab=Cash cow

[Helge_LarsenPI-redaktør]

[Helge_LarsenPI-redaktør]

JNJ-7564 GPRC5D/CD3:
http://www.genmab.com/product-pipeline/products-in-development/jnj-63709178

[gentogen]

Nu vi er ved det, så er det aldroig lykkedes mig at finde ud af, om dette også er med Genmab "JNJ-67371244 (Bispecific Antibody Targeting CD33 and CD3), in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) ???